AbbVie: acquisition of ImmunoGen finalized
The transaction gives the healthcare group access to Elahere, the first and only antibody-drug conjugate approved by the US FDA for the treatment of ovarian cancer.
AbbVie confirms its full-year 2024 adjusted EPS target range of $11.05-11.25, but lowers its first-quarter range by four cents to between $2.26 and $2.30, due to the acquisition of ImmunoGen.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction